Section Review Anti-infectives: Recent developments in 14- and 15-membered macrolides

References

• KLTRATH P, JONES P, EGAN R, PERUN T: Acid degradation of erythromycin A and erythromycin B. Experienta (1971) 27:362.
   PubMedGoogle Scholar
• ITOH Z, NAKAYA M, SUZUKI T, FIIRAL H, WAKABAYASHI K: Erythromycin mimics exogenous motilin in gastro-intestinal contractile activity in the dog. Am. J. Physiol (1984) 10:G688–G694.
   Google Scholar
• KIRST H: Semi-synthetic derivatives of erythromycin. Progress Med. Chem. (1993) 30:57–87.
   PubMedGoogle Scholar
• GASC J, D'AMBRIERES S, LUTZ A, CHANTOT J: New ether oxime derivatives of erythromydn A. A structure-activ-ity relationship study. J. Antibiotics (1991) 44:313–330.
   PubMedGoogle Scholar
• PHILLIPS I, PECHERE J, DAVIES A, SPELLER D (Eds.): Roxithromycin: a new macrolide. J. Antimicrob. Chem other. (1987) 20(Suppl. B):1–183.
   Google Scholar
• BARLAM T, NEU H: In vitro comparison of the activity of RU 28965, a new macrolide, with that of erythromy-cin against aerobic and anaerobic bacteria. Antimicrob. Agents Chemotber. (1984) 25:529–531.
   PubMed Web of Science ®Google Scholar
• CHANTOT J, BRYSKIER A, GASC J: Antibacterial activity of roxithromycim a laboratory evaluation. J. Antibiotics (1986) 39:660–668.
   PubMed Web of Science ®Google Scholar
• JONES R, BARRY A, THORNSBERRY C: In vitro evaluation of three new macrolide antimicrobial agents, RU 28965, RU 29065, and RU 29702 and comparison with other orally administered drugs. Antimicrob. Agents Chemother. (1983) 24:209–215.
   PubMed Web of Science ®Google Scholar
• ARONOFF S, LAURENT C, JACOBS M: In vitro activity of erythromycin, roxithromycin, and CP62993 against common pediatric pathogens. J. Antimicrob. Chemother. (1987) 19:275–276.
   PubMed Web of Science ®Google Scholar
• JORGENSEN J, REDDING J, HOWELL A: In vitro activity of the new macrolide antibiotic roxithromycin (RU 28965) against clinical isolates of Haemophitus influenzae. Antimicrob. Agents Chemother. (1986) 29:921–922.
   PubMed Web of Science ®Google Scholar
• MENTIS A, TZOUVELEKIS L, TZELEPI E, IOSSIFIDOU I, KARAFOTIS F: Susceptibility of Cblamydia tracbomatis strain isolated in Greece to erythromycin and roxithromycin. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 149.
   Google Scholar
• SAMARA Z, ROSENBERG S, KAUFMAN S: Antibiotic sus-ceptibility of urea-plasma urealyticum. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 146.
   Google Scholar
• JOHNSON, ET AL: Antimicrobial activity of ten macrolide, liscosamine and streptogramin drugs tested against Legionella species. Ear. J. Clin. Microbiol. Infect. Dis. (1992) 11:751–755.
   PubMed Web of Science ®Google Scholar
• ZANA J, MUFFAT-JOLY M, THOMAS D, ORFILA J, SALAT- BAROUX J, POCIDALO J: Roxithromycin treatment of mouse chiamydial salpingitis and protective effect on fertility. Antimicrob. Agents Chemother. (1991) 35:430–435.
   PubMed Web of Science ®Google Scholar
• RAS G, ANDERSON R, TAYOR G, SAVAGE J, VAN NIEICERK E, JOONE G, KOORNHOF H, SAUDERS J, WILSOM R, COLE P: Clindamycin, erythromycin, and roxithromycin in- hibit the proinflammatory interaction of Pseudo-monas aeruginosa pigments with human neutrophils in vitro. Antimicrob. Agents Chemother. (1992) 36:1236–1240.
   PubMed Web of Science ®Google Scholar
• PRUUL H, MCDONALD P: Potentiation of antibacterialactivity of azithromycin and other macrolides by nor-mal human serum. Antimicrob. Agents Chemother. (1992) 36:1046.
   Google Scholar
• WISE R, KIRKPATRICK B, ASHBY J, ANDREW J: Pharma-cokinetics and tissue penetration of roxithromycin • after multiple dosing. Antimicrob. Agents Chemother. (1987) 31:1051–1053.
   PubMed Web of Science ®Google Scholar
• HALSTENSON C, OPSHAL J, SCHWENK M, KOVARIK J, PURIS, HO I, MATZKE G: Disposition of roxithromycirt in • patients with normal and severely impaired renal func-tion. Antimicrob. Agents Chemother. (1990) 34:385–389.
   PubMed Web of Science ®Google Scholar
• ODENHOLT-TORNQVIST I, LOWDIN E, CARS D: Postanti-biotic Sub-MIC effects of vancomycin, roxithromycin, sparfloxacin and amikacin. Antimicrob. Agents Chemother. (1992) 36:1852–1858.
   PubMed Web of Science ®Google Scholar
• NILSEN D: Plasma pharmacokinetics of macrolides withreference to total and free concentrations. 2nd Interna-tional conference on the macrolides, azalides and strepto-gramins. Venice, Italy (1994), Abstract No. 211.
   Google Scholar
• HALSTENSON C,OPSAHL J, SCHWENK M, KOVARIK J, PURIS, HO I, MATZKE G: Disposition of roxithromydn in patients with normal and severely impaired renal func-tion. Antimicrob. Agents Chemother. (1990) 34:385–389.
   PubMed Web of Science ®Google Scholar
• GASSER R, WENDELIN I, REISINGER E, KLEIN W: Com-bined therapy with roxithromycin and co-trimoxazok of late lytne disease. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 310.
   Google Scholar
• BURETTE A, GLLTPCZYNSKI Y, DEPREZ C, JACOBS D: Lansoprazole plus roxithromycin and metronidazole for eradication of H. pylori of a pilot study. 2nd Interna-tional conference on the macrolides, azalides and strepto-gramins. Venice, Italy (1994), Abstract No. 319.
   Google Scholar
• PALOMBINI B, VILLANOVA C, STOLZ D: Treatment ofatypical community acquired pneumonia (CAP) with roxithromycin (ROX): preliminary results of an open study. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 279.
   Google Scholar
• BRAMBILLA C: Muhicentre study to evaluate the efficacyand safety of roxithromycin (once-a-day) vs erythro-mycin in the treatment of community acquired pneu-monia. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 273.
   Google Scholar
• LORENZ J: Multicentre study of the efficacy and toler-ability of roxithromycin in the treatment of respiratory tract infections. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 226.
   Google Scholar
• BAJARES DE ULUE M, MAZZAU DE ILJA R, SANTIAGO A,FERRINI A, ADAMES Z: Comparative study between roxithromycin and doxycyline in mycoplasma and chlamydial gynaecological infections. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 321.
   Google Scholar
• BEGUE P, ASTRUC J, SAFRAN C, DUBOIS A, ROSTAND A:The overall safety of oral roxithromycin in paediatic clinical studies. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 224.
   Google Scholar
• WILSON J, HANNAN P, SHILLINGFORD C, KNOWLES D: Biological property of ER 42859, a novel erythromycin derivative. J. Antibiotics (1989) 42:454–462.
   PubMed Web of Science ®Google Scholar
• MASSEY E, KITCHELL B, MARTIN L, GERZON K: Antibac-terial activity of 9(S)-erythromycylamine-aldehyde condensation products. J. Med. Chem. (1974) 17:105–107.
   PubMed Web of Science ®Google Scholar
• SAKAKABARA H, OMURA S (Eds.): Macrolide antibiotics: chemistry, biology, and practice. Academic Press, Inc., Orlando (1984).
   Google Scholar
• KIRST H, WIND J, LEEDS J, WILLARD K, DEBOND M, BONJOUKLIAN R, GREENE J, SULLIVAN K, PASCHAL J, DEETER J, JONES N, OTT J, FELTY-DUCKWORTH A, COUNTER F: Synthesis and structure-activity relation-ship of new 9-N-alkyl derivatives of 9(S)-erythromycy-larnine. J. Med. Chem. (1990) 33:3086–3094.
   PubMedGoogle Scholar
• COLBERT W, TURK J, WILLIANS P, BUENING M: Cardio-vascular and autonomic pharmacology of the macrolide antibiotic LY281389 in anesthetized beagles and isolated smooth and aortic muscles. Antimicrob. Agents Chemother. (1991) 35:1365–1369.
   PubMed Web of Science ®Google Scholar
• KIRST H, ALLEN N, LEEDS J, TOTH J, DEBONO M, WILLARD K, COUNTER F: Synthesis and evaluation of macrolide derivatives which demonstrate in vitro activity against inducibly and constitutively MIS-resistant strains of Staphylococci. 30th Interscience Conf on Antimicrob. Agents Chemother. Atlanta, US (1990), Abstract No. 806.
   Google Scholar
• -MARING C, KLEIN L, PARIZA R, LARTEY P, GRAMPOVNIK D, YEUNG C, BUYTENDORP M, HARDY D: Synthesis and SAR of derivatives of 9(R)-erythromycylamine. 29th Interscience Conf on Antimicrob. Agents Chemother. Hous-ton, US (1989), Abstract No. 1023.
   Google Scholar
• HARDY D, VOJTKO C, BEYER J, HENSEY D, MARING C, KLEIN L, PARIZA R, LARTEY P, CLEMENT J: In vitro evaluation of a new series of (9R)-amino-9-deoxo-erythromycin analogs. 29th Interscierzce Conf. on Antimi-crob. Agents Chemother. Houston, US (1989), Abstract No. 1024.
   Google Scholar
• LUGER P, MAIER R: Molecular structure of 9-deoxy-11- deoxy-9,11-(imino(2-(2-methoxyethoxy) ethyl idene)oxy)-(9S)-erythromycin, a new erthromycin de-rivative. J. Czyst. Mol. Struct. (1979) 9:329–338.
   Web of Science ®Google Scholar
• HARDY D, HENSEY D, BEYER J, VOJTKO C, MCDONALD E, FERNANDES P: Comparative in vitro activities of new14-, 15-, and 16- membered macrolides. Antimicrob. Agents Chemother. (1988) 32:1710–1719.
   PubMed Web of Science ®Google Scholar
• YU K, NEU H: In vitro activity of dirithromycin (LY •237216) compared with activities of other macrolide antibiotics. Antimicrob. Agents Chemother. (1990) 34:1839–1842.
   PubMed Web of Science ®Google Scholar
• COUNTER F, ENSMINGER P, PRESTON D, wu L, GREENE J, FELTY-DUCKWORTH A, PASCHAL J, KIRST H: Synthesis and antimicrobial evaluation of dirithromycin (A5E 136; LY 237216), a new macrolide antibiotic derived from erythromycin. Antimicrob. Agents Chemother. (1991) 35:1116–1126.
   PubMed Web of Science ®Google Scholar
• KIRST H, PRESTON D, ALBORN J, CREEMER L: Determination of the inherent antimicrobial activity of dirithromycin by measuring cell-free inhibition of pro-tein synthesis. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 102.
   Google Scholar
• MTAIRAG E, ABDELGHAFFAR H, DERRIENNIC M, SIDES G, LABRO M: Mechanism of dirithromycin (DIR) and erythromycylamine (ECM) uptake by human neutro-phils (PMN). 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 159.
   Google Scholar
• ABDELGHAFFAR H, MTAIRAG E, LABRO M: Effect of dirithromycin and erythromycylamine on human neu-trophildegranulation. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 160.
   Google Scholar
• LABRO M, ABDELGHAFFAR H, DERREENNIC M: Compari-son of dirithromycin (MR), erythromycylamine (ECM) and roxithromycin (R) for their modulation of the human neutrophil (PMN) oxidative burst in vitro. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 162.
   Google Scholar
• LABRO M, MTAIRAG E: Antibacterial synergy between dirithromycin (DIR), erythromycylamine (ECM) and neutrophils (PMN). 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 163.
   Google Scholar
• SIDES G, CERIMELE B, BLACK H, BUSCH U, DESANTE K: Pharmacokinetics of dirithromycin. J. Antimicrob. Chemother. (1993) 31(Suppl. C):65–75.
   Google Scholar
• MAZZEI T, SURRENTI C, NOVELLI A, BIAGINI M, SURRENTI E, PERITI P: Single dose pharmacokinetics of diritbromycin in patients with impaired hepatic func-tion. 33th Interscience Conf. on Antimicrob. Agents Chemotber. New Orleans, US (1993), Abstract No. 410.
   Google Scholar
• MCCARTY J, HUCK W, GUTHRIE E, SMIETANA M, ADAMS K, CONFORTI P, WILSON M, SIDES G: Dirithromycin versus penicillin VK in the treatment of streptococcal pharyngitis and/or tonsillitis. 33th Interscience Conf. on Antimicrob. Agents Chemother. New Orleans, US (1993), Abstract No. 399.
   Google Scholar
• McCARTY J, GUTHRIE E, HUCK W, JACKS D, HARRIS J, SIDES G: Dirithromycin verus erythromycin base in streptococcal pharyngitis/tonsillitis. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 242.
   Google Scholar
• SIDES G, CONFORTI P, WILSON M, SMIETANA M: Pooled analysis of three dirithromycin pharyngitis clinical trials. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 243.
   Google Scholar
• SALISBURY J, CHIULLI R, TAYOR J, ALDRICH H, JONES C,SIDES G, CONFORTI P, WILSON M: Dirithromycin 5 days versus erythromycin 7 days in acute superimposed on chronic (ASOC) bronchitis. 33th Interscience Conf. on Antimicrob. Agents Chemother. New Orleans, US (1993), Abstract No. 400.
   Google Scholar
• SIDES G, SMIETANA M, CONFORTI P, WILSON M, DERRIEN-NIC M: Acute exacerbation of chronic (aeoc) bronchitis: an analysis based on stratification by severity. 2nd International conference on the macrolides, azalides and strepto-gramins. Venice, Italy (1994), Abstract No. 254.
   Google Scholar
• LODE H, AMITS J: Clinical efficacy of dbithromycin verus roxithromycin in acute bacterial exacerbration of chronic bronchitis. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 257.
   Google Scholar
• VARANESE L, SIDES G: Dirithromycin efficacy in skinand skin structure infections. 2nd International confer-ence on the macrolides, azalides and strepto-gramins. Venice, Italy (1994), Abstract No. 300.
   Google Scholar
• DILORENZO P, SHUPBACH C, SALOSBURY J, OGBON-NAYA K, RUOFF G, DAVENPORT C, CONFORTI P, SIDES G, WILSON M: Dirithromydn 5 days versus erythromy-cin 7 days in skin and skin soft tissue infections. 33th Interscience Conf on Antimicrob. Agents Chemother. New Orleans, US (1993), Abstract No. 402.
   Google Scholar
• SMITS J: The efficacy of dirithromycin in patients withatypical pneumonia. 2nd International conference on the macrolides, azalides and strepto-gramins. Venice, Italy (1994), Abstract No. 300.
   Google Scholar
• HUCK W, GUTHRIE E, SMITS P, BLACK S, FERENDO R, HARRIS J: Dirithromychi versus erythromycin base in lobar pneumonia/bronchopneumonia, or pneumonia due to Mycoplasma,Legionella or Chantydia infection. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 286.
   Google Scholar
• ROUVEIX B: Drug interactions with dirithromycin. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 219.
   Google Scholar
• FINCH R, HAMILTON-MILLER J, LOVERING A (Eds.): Dirithromycin: a new once-daily macrolide. j Antimi-crob. Chemother. (1993) 31(Suppl. C).
   Google Scholar
• FREIBERG L, EDWARDS C, BACINO D, SEIF L, LARTEY P, WHITTERN D: Synthesis of amino analogs of (9S,11S)-9-deoxo-12-deoxy-9,12-epoxyerythromycin A (4–63483) and 9(S)-9-deoxo-11,12-dideoxy-9,12-epoxy-11-oxo-erythromycin A (4–63881). 29th Interscience Conf. on Antimicrob. Agents Chem other. Houston, US (1989), Abstract No. 1029.
   Google Scholar
• HARDY D, SWANSON R, FREIBERG L, LARTEY P, CLEMENTT: In vitro activity and in vivo efficacy of a new series of 9,12-epoxyerythromycin derivatives. 29th Inter-science Conf on Antimicrob. Agents Chemother. Houston, US (1989), Abstract No. 1030.
   Google Scholar
• MARSH K, QUIGLEY S, CULBERTSON S, FREIBERG L, BACHINO D, EDWARDS C, MCDANIEL D, LARTEY P: Phar-macokinetic behavior of a series of 9,12-epoxyery-thromycin derivatives in dog and monkey. 29th Interscience Conf on Antimicrob. Agents Chemother. Hous-ton, US (1989), Abstract No. 1031.
   Google Scholar
• HARDY D, SWANSON R, SHIPKOWITZ N, FREIBERG L, LARTEY P, CLEMENT J: In vitro activity and in vivoefficacy of a new series of 9-deoxo-12-deoxy-9,12-epoxyerythromycin A derivatives. Antimicrob. Agents Chemother. (1991) 35:922–928,
   PubMed Web of Science ®Google Scholar
• JOHNSON P, FREIBERG L, MILLER M, LARTEY P, MARTIN J: Accumulation and egress of A-69334, a novel 9,12-epoxy erythromycin derivative, into bacteria and human PMNs. 30th Interscience Conf on Antimicrob. Agents Chemother. Atlanta, US (1990), Abstract No. 813.
   Google Scholar
• CLEMENT J, SHIPKOWITZ N, SWANSON R, LARTEY P: Efficacy of a 9,12-epoxy erythromycin derivative, A-69334, in H. influenzae induced otitis media in gerbils. 30th Interscience Conf on Antimicrob. Agents Chernother. Atlanta, US (1990), Abstract No. 814.
   Google Scholar
• NELLANS H, PETERSEN A, FREIBERG L, LARTEY P: Evalu-ation of a new 9,12-epoxyerythromycin derivative (A-69334) in an anesthetized dog gastrointestinal motility modeL 30th Interscience Conf on Antimicrob. Agents Chemother. Atlanta, US (1990), Abstract No. 815.
   Google Scholar
• MARSH K, CULBERTSON S, FREIBERG L, SWANSON R, CLEMENT J, LARTEY P: Pharmacokinetic behavior of (9S,11S)-11-amino-9-deoxo-11,12-dideoxy erythromy-cin in dog, monkey and mouse. 30th Interscience Conf. on Antimicrob. Agents Chemother. Atlanta, US (1990), Ab-stract No. 816.
   Google Scholar
• JONES A: New macrolide antibiotics: synthesis of a 14-membered a721itie. J. Org. Chem. (1992) 57:4361–4367.
   Web of Science ®Google Scholar
• JONES A, HERBERT C: The in vitro profile of selected 14-membered azalides. J. Antibiotics (1992) 45:1785–1791.
   PubMed Web of Science ®Google Scholar
• NAKATA M, TAMAI T, MIURA Y, IUNOSHITA M, TATSUTA K: Synthetic studies of erythromycin derivatives: syn-thesis and antimicrobial activities of 3'-epi-erythromy-cin A and (9S)-11-dehydrox-y-9-deoxo-9-hydroxy-11-oxoerythromycin A. J. Antibiotics (1993), 46:813–826.
   PubMed Web of Science ®Google Scholar
• TOSCANO L, FIORIELLO G, SPAGNOL R, CAPPELLTTI L, ZANUSO G: New fluorinated erythromycin obtained by mutasynthesis. J. Antibiotics (1983) 36:1439–1450.
   PubMed Web of Science ®Google Scholar
• TOSCANO L, FIORIELLO G,SILINGARDI S, INGLESI M: (8S)-8-Fluoroerythronolkie B, potential substrate for the biological synthesis of new macrolide antibiotics. Tet-rahedron (1984) 40:2177–2181
   Google Scholar
• GIALDRONI-GRASSI G, ALESINA R, BERSANI C, FERRARAA, FIETTA A, PEONA V: in vitro activity of flurithromycin, a novel macrolide antibiotic. Chemioterapia (1986) 5:177–184.
   PubMedGoogle Scholar
• NORD C, LANDMARK A, PERSSON I: Comparative antimi- crobial activity of the new macrolide flurithromycin against respiratory pathogens. Eur. j CUn. Microbiol. Infect. Dis. (1988) 7:71–73.
   PubMed Web of Science ®Google Scholar
• HARDCASTLE J (Ed.): Pharmaprojects (Therapeutic Catagories, main volume). PJB Publications, Richmond, UK (1991).
   Google Scholar
• McALPINE J, SWANSON S, WHITTEN D, BUKO A, WEBER J: 6-Deoxyerythromycin L Producing organism, isola-tion, separation and structural elucidation. 30th Inter-science Conf. on Antimicrob. Agents Chemother. Atlanta, US (1990), Abstract No. 810.
   Google Scholar
• CLEMENT J, HANSON C, SHIPKOWITZ N, HARDY D, SWANSON R: 6-Deoxyerythromycin IL Comparative in vitro activity and in vivo efficacy. 30th Interscience Conf. on Antimicrob. Agents Chemother. Atlanta, US (1990), Abstract No. 811.
   Google Scholar
• FAGHIN R, PAGANO T, McALPINE J, TANAKA K, PLATTNER J, LARTEY P: Acid degradation studies of 6-deoxy-erythromycin A. J. Antibiotics (1993) 46:698–700.
   PubMed Web of Science ®Google Scholar
• KATZ L, HUTCHINSON R: Genetic engineering of antibi- otic producing organism. Ann. Rep. Med. Chem. (1992) 27:129–138.
   Google Scholar
• KATZ L, DONADIO S: Polyketide synthesis: prospects for hybrid antibiotics. Ann. Rev. Microbiol. (1993) 47: 875–912.
   PubMed Web of Science ®Google Scholar
• WEBBER J, LEUNG J, SWANSON S, IDLER K, MCALPINE J: An erythromycin derivative produced by targeted gene disruption in Saccbaropolyspora mytbraea. Science (1991) 252:114–117.
   PubMed Web of Science ®Google Scholar
• DONADIO S, STASSI D, McALPINE J, STAVER M, SHELDON P, JACKSON M, SWANSON S, WENDT-PIENKOWSKI E,WANG Y, JAVES R, HUTCHINSON C, KATZ L: Recent developments in the genetics of erythromycin forma-tion. Ind. Microorganism Basic and Applied Mol. Genetics (1993):257–265.
   Google Scholar
• MORIMOTO S, MISAWA Y, ADACHI T, NAGATE T, WATANABE Y, OMURA S: Chemical modification of erythromy-cins IL Synthesis and antibacterial activity of O-alkyl derivatives of erythromycin A. J. Antibiotics (1990) 43:286–305.
   PubMed Web of Science ®Google Scholar
• MORIMOTO S, TAKAHASHI Y, WATANABE Y, OMURA S: Chemical modification of erythromycin L Synthesisand antibacterial activity of 6-0-methylerythromycin A. J. Antibiotics (1984) 37:343–345.
   Google Scholar
• CHIN N, NEU N, LABTHAVIKUL P, SAHA G, NEU H: Activity of A-56268 compared with that of erythromycin and other oral agents against aerobic and anaerobic bacte-ria. Antimicrob. Agents Chemother. (1987) 31:463–466.
   PubMed Web of Science ®Google Scholar
• BARRY A, THORNSBERRY C, JONES R: In vitro activity of a new macrolide, A-56268, compared with that of roxithromycin, erythromycin, and c.lindamycin. An-timicrob. Agents Chemother. (1987) 31:463–466.
   PubMedGoogle Scholar
• JANSSON L, KALIN M: Comparative in vitro activity of A56268 against respiratory tract pathogens. Eur. J. din. Microbiol. Infect. Dis. (1987)6:494–496.
   Web of Science ®Google Scholar
• FERNANDES P, BAILER R, SWANSON R, HANSON C, McDONALD E, RAMER N, HARDY D, SHIPKOWITZ N, BOWER R, GADE E: in vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide. Antimicrob. Agents Chemother. (1986) 30:865–873.
   PubMed Web of Science ®Google Scholar
• FLOYD-REISING S, HINDLER J, YOUNG L:In vitro activity of A-56268 (TE-031), a new macrolide antibiotic, com-pared with that of erythromycin and other antimicro-bial agents. Antimicrob. Agents Chemother. (1987) 31:640–642.
   PubMed Web of Science ®Google Scholar
• JONES R, BARRY A, THORNSBERRY C: The antimicrobial activity of A-56268 (TE-031) and roxithromycin (RU 965) against Legionella using both microdilution method. J Antimicrob. Chemother. (1987) 19:841–842.
   PubMed Web of Science ®Google Scholar
• LIEBERS D, BALTCH A, SMITH R, HAMMER M, CONROY J: Susceptibility of Legionella pneumopbila to eight an-timicrobial agents including four macrolides in differ-ent assay conditions. J. Antimicrob. Chemother. (1989) 23:37–41.
   PubMed Web of Science ®Google Scholar
• EUOPOULOS G, REISZNER E, FERRARO M, MOELLERING R: Comparatve in vitro activity of A-56268 (TE-031), a new macrolide antibiotic. J. Antimicrob. Chemot her. (1988) 21: 671–675.
   Google Scholar
• BENSON C, SEGRETI S, BEAUDETTE F, HINES D,GOODMAN L, KAPLAN R, TRENHOLME G: In vitro activity of A-56268 (TE-031), a new macrolide, compared with that of erythromycin and clindamycin against selected gram-positive and gram-negative organism. Antimicrob. Agents Chemother. (1987) 31:328–330.
   PubMed Web of Science ®Google Scholar
• BARRY A, FERNANDES P, JORGENSEN J, THORNSBERRY C, HARDY D, JONES R: Variability of clarithromycin and erythromycin susceptibility tests with Haemopbilus infissenzae in four different broth media and correla-tion with the standard disk diffusion test/. ain. Micro-biol. (1988) 26:2415–2420.
   Google Scholar
• FERNANDES P, HARDY D, BAILER R, MCDONALD E, PINTAR J, RAMER N, SWANSON R, GADE E: Susceptibility testing of macrolide antibiotics against Haemopbilus influenzae and correlation of in vitro results with in vivo efficacy in a mouse septicemia modeL Antimicrob. Agents Chemother. (1987) 31:1243–1250.
   PubMed Web of Science ®Google Scholar
• LIEBERS D, BALTCH A, SMITH R, HAMMER M, CONROY J, SHAYEGANI M: Comparative in vitro activities of A-56268 (TE-031) and erythromycin against 306 clinical Isolates. J. Antimicrob. Chemother. (1988) 21:565–570.
   PubMed Web of Science ®Google Scholar
• HARDY D, SWANSON R, RODE R, MARSH K, SHIPKOWITZ N, CLEMENT J: Enhancement of the in vitro and in vivo activity of clarithromycin against Haemopbilus influ-enzae by 14-hydroxy clarithromycin, its major metabo-lite in human. Antimicrob. Agents Chemother. (1990) 34:1407–1413.
   PubMed Web of Science ®Google Scholar
• JORGENSEN J, MAHGER L, HOWELL A: Activity of clarithromycin and its prindpal human metabolite against Haemopbilus influenzae. Antimicrob. Agents Chemother. (1991) 35:1524–1526.
   PubMed Web of Science ®Google Scholar
• VALLEE E, AZOULAY-DUPUIS E, SWANSON R, BERGOGNE-BEREZIN E, POCIDALO J: Individual and combined ac-tivities of cLarithromycin and its 14-hydroxy metabolite In murine model of Haemopbilus influenzae infection. J. Antimicrob. Chemother. (1991) 27(Suppl. A):11–18.
   Google Scholar
• SCAGLIONE F, GOLDMAN C: Interaction of erythromy-cin, clarithromycin, and the 14-hydroxyclarithromycin with gram-negative and -positive bacterial cells and ribosomes. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 113.
   Google Scholar
• CHIN N, DELLA-LATTA P, WHII LER S, NEU H: In vitro activity of clarithromycin and 14-hyciroxy-clarithromy-cin verus H. influenzae and S. pneumoniae, group A and group B Streptococcus in the New York area. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 109.
   Google Scholar
• BARRY A: Antibacterial activity of darithromycin, 14-hydroxy clarithromycin and five other oral agents against respiratory pathogens from outpatients within the United States. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 109.
   Google Scholar
• WANES K, CASSELL G, CANUPP K, FERNANDES P: In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and arylfluoroquinolones. Antimicrob. Agents Chemother. (1988) 32:1500–1502.
   PubMedGoogle Scholar
• BOWER W, SHAW C, CHAN D, BLACK W: In vitro activity of Ro 15-8074, Ro 19-5247, A-56268 and roxithromycin (RU 28965) againstNeisseriagonorrboeae and Chiang-din tracbomatis. Antimicrob, Agents Chemother. (1987) 31:470–472.
   PubMedGoogle Scholar
• EGRETI J, ICESSLER H, KAPELL K, TRENHOLME G: In vitro activity of A-56268 (TE-031) and four other antimicro-bial agents against Cblantydia tracbomatis. Antimicrob. Agents Chemother. (1987) 31:100–101.
   PubMedGoogle Scholar
• DANGOR Y, MILLER S, DALFXPOSTO F, KOORNHOF H: Antimicrobial susceptibility of Southern African iso-lates of Haemopbilus ducreyi. Antimicrob. Agents Chemother. (1988) 32:1458–1460.
   PubMed Web of Science ®Google Scholar
• BIEHLE 3, CAVALIERI S: In vitro susceptibility of Myco- bacterium kansasii to clarithromycin. Antimicrob. Agents Chemother. (1992) 36:2039–2041.
   PubMed Web of Science ®Google Scholar
• BERLIN O, YOUNG L, FLOYD-REISING S, BRUCKNER D: Comparative in vitro activity of new macrolide A-56268 against mycobacteria. Eur. j Clin. Microbiol. Infect. Dis. (1987) 6:486–487.
   Web of Science ®Google Scholar
• BROWN B, WALLACE R, ONYL G, DE ROSAS V, WALLACE R: Activities of four macrolides, including darithromy-cin, against Mycobacterium fortuitum, Mycobacterium cbelonae, and M. chelonae-like organisms. Antimicrob. Agents Chemother. (1992) 36:180–184.
   PubMed Web of Science ®Google Scholar
• MOINARD D, BOURRIED Y, BEMER-MELCHIOR P, RAFFI F: Activity of clarithromycin against Mycobacterium avium complex determined with Bactec: pH effect. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 156.
   Google Scholar
• SPANGLER S, JACOBS M, SPIELBAUM P: Susceptibility of 119 anaerobes to erythromycin, azithromycin, clarithromycin and roxithromycin. 33rd Interscience Conf on Antimicrob. Agents Chemother. New Orleans, US (1993), Abstract No. 251.
   Google Scholar
• SPANGLER S, JACOBS M, SPIELBAUM P: Effect of CO2 on susceptibilities of anaerobes to erythromycin, az-ithromycin, clarithromycin, and roxithromydn. An-timicrob. Agents Chemother. (1994) 38:211–216.
   PubMed Web of Science ®Google Scholar
• CHIN N, NEU N, LABTHAVLICUL P, SAHA G, NEU H: Activity of A-56268 compared with that of erythromycin and other oral agents against aerobic and anaerobic bacte-ria. Antimicrob. Agents Chemother. (1987) 31:463–466.
   PubMed Web of Science ®Google Scholar
• TATEDA K, HIRAKATA Y, FURUYA N, OHNO A, YAMA- GUCHI K: Effects of sub-MICs of erythromycin and other macrolide antibiotics on serum sensitivity of Pseudo-monas aeruginosa. Antimicrob. Agents Chemother. (1993) 37:675–680.
   PubMed Web of Science ®Google Scholar
• ANAKA S, JONES R, LARTEY P: New and unusal antimi- crobial properties of clarithromycin. 2nd International conference on the macrolides, azalides and streptogramins, Venice, Italy (1994), Abstract No. 110.
   Google Scholar
• HARDY D, HANSON C, HENSEY D, BEYER J, FERNANDES P: Susceptibility of Campylobacter pylori to macrolides and ftuoroquinolones. J. Antimicrob. Chemother. (1988) 22:631–636.
   PubMed Web of Science ®Google Scholar
• GOLDMAN R, ZAKULA D, CAPOBIANCO 3: Tight binding of clarithromycin, 14-hydroxyclarithromycin and erythromycin to Helicobacter pylori ribosomes. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 101.
   Google Scholar
• FLAMM R, BEYER J, TANAKA S, CLEMENT J: Kill kinetics and activity of antibiotics against Helicobacter pylori. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 139.
   Google Scholar
• PREAC-MURSIC V, WILSKE B, SCHIERZ G, SUP E,GROP B: Comparative antimicrobial activity of the new macrolides against 13orrelia burgdotferi. Eur. J. Clin. Microbiol. Infect. Dir. (1989) 8:651–653.
   PubMed Web of Science ®Google Scholar
• GARCIA-RODRIGUEZ J,BELLIDO J, FRESNADILLO M, TRu- JILLANO I: In vitro activity of new macrolides and rifape,ntine against Brucella spp. Antimicrob. Agents Chemother. (1993) 37:911–913.
   PubMed Web of Science ®Google Scholar
• MONEIB N, SHIBL A, EL-SAID M, EL-MASRY E: MaCrOlides induced suppression of virulence factors produced byStaphylococcus aureus. J. Chemother. (1993) 5:289–292.
   PubMed Web of Science ®Google Scholar
• FERNANDES P, SWANSON R, HARDY D, MCDONALD E, RAMER N: Effect of dosing intervals on efficacy of clarithromycin and erythromycin in mouse infection models. Drugs Exp. Clin. Res. (1988) 14:441–444.
   PubMedGoogle Scholar
• NEU H: The development of macrolides: clarithromycin in perspective. J. Antimicrob. Chemother. (1991) 27(Suppl.A):1–9.
   Google Scholar
• CHU S, WILSON D, EASON C, DEATON R: Single and multidose pharmacokinetics (PlCs) of clarithromycin (C). 30th Interscience Conf. on Antimicrob. Agents Chemother. Atlanta, US (1990), Abstract No. 759.
   Google Scholar
• CHU S, SENNELLO L, BUNNELL S, VARGA L, WILSON D, SONDERS R: Pharmacokinetics of clarithromycin, a new macrolide, after single ascending oral dose. Antimicrob. Agents Chemother. (1992) 36:2447–2453,
   PubMed Web of Science ®Google Scholar
• SCAGLTONE F, DEMARTINI G, FRASCHINI F: Distribution of clarithromycin to intracellular and extravascular sites of infection: an overview. 2nd International confer-ence on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 207.
   Google Scholar
• FISH D, GOTFRIED M, DANZIGER L, RODVOLD K: Pene- tration of clarithromycin into lung tissues from pa-tients undergoing lung resection. Antimicrob. Agents Chemother. (1994) 38:876–878.
   PubMed Web of Science ®Google Scholar
• GAN V, CHU S, KUSMIESZ H, CRAFT J: Pharmacokinetics of a clarithromycin suspension in infants and children.Antimicrob. Agents Chemotber. (1992) 36:2478–2480.
   PubMed Web of Science ®Google Scholar
• SIEPMAN N, PIXTON G, NOTARIO G: Clarithromycin in the treatment of S. pneumoniae infections. 2nd Interna-tional conference on the macrolides, azalides and strepto-gramins. Venice, Italy (1994), Abstract No. 260.
   Google Scholar
• CRAFT C,STAMLER D: The role of clarithromycin In patients with Legionella pneumonia. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994),
   Google Scholar
• DLTBOIS J, SAINT PIERRE C, PIZZUTI D, SIEPMAN N: Clinical success of clarithromycin in bronchitis and sinusitis for the treatment of H. influenzae infections. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 246.
   Google Scholar
• STAMLER D, CRAFT C, SIEPMAN N: Clarithromycin 250 mg BID for the treatment of H. influenzae infections. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 261.
   Google Scholar
• NOTARIO G, SIEPMAN N, DEVCICH K: Clarithromycin in the treatment of acute bacterial exacerbation of chronic bronchitis (AECB). 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 251.
   Google Scholar
• SIEPMAN N, NOTARIO G: Treatment of acute bacterial exacerbation of chronic bronchitis (AECB) with clarkhromycin in smokers. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 252.
   Google Scholar
• MACKIN J, COLES S: Safety and Efficacy of clarithromy- cin compared with amoxycillin or cefaclor in children with lower respiratory tract infections. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 265.
   Google Scholar
• GEHANNO P, CHAUVIN J, HAZEBROUCQ J: Clarithromy-cin versus amoxicillin/clavulanic add in acute maxil-lary sinusitis in adults. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 237.
   Google Scholar
• DUBOIS J, SAINT PIERRE C, DEVCICH K: Clarithromycin in the treatment of acute maxillary sinusitis. 2nd Inter-national conference on the macrolides, azalides and strepto-gramins. Venice, Italy (1994), Abstract No. 236.
   Google Scholar
• SPIRITUS E: Safety of clarithromycin in elderly patients. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 213.
   Google Scholar
• REINHARZ D, TESSIER G, LAURIER C, CONTANDRIOPOU-LOS A, CHAMPAGNE F, TRABUT I, KENNEDY W, ZAKHARI R: Pharacoeconomic evaluation of clarithromycin for the treatment of community-acquired pneumonia. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 275.
   Google Scholar
• STEIN G, MANTZ S: Antibiotic utilization and cost analy-sis in hospitalized patients with community acquired pneumonia (CAP). 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 275.
   Google Scholar
• COLES S, ADDLESTONE M, KAMDAR M, MACKLIN J: Clarithromycin vs amoxycillin suspensions in the treat-ment of acute otitis media in children. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 235.
   Google Scholar
• MCCARTY J, GOOD C, RENTERIA A, SIEPMAN N, CRAFT J: Comparative safety and efficacy of darithromydn (C) vs amoxicillin/clavulanate (A/C) or cefaclor (Cl) in the treatment of acute otitis media (ADM) in children. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 234.
   Google Scholar
• GELBER R, SIU P,TSANG M, MURRAY L: Activities of various macrolide antibiotics against Mycobacterium leprae infection in mice. Antimicrob. Agents Chemother. (1991) 35:760–763.
   PubMed Web of Science ®Google Scholar
• UNITED NATIONS DEVELOPMENT PROGRAMME/WORLD BANK/WORLD HEALTH ORGANIZATION SPECIAL REPORT PROGRAMME FOR RESEARCH AND TRAINING IN TROPI-CAL DISEASE: Seventh programme report. WHO, Geneva (1985).
   Google Scholar
• CHAN G, GARCIA-IGNACIO B, CHAVEZ V, LIVELO J, JIME- NEZ C, PARRILLA L, FRANZBLAU S: Clinical trial of darithromydn for lepromatous leprosy. Antimicrob. Agents Chemother. (1994) 38:515–517.
   PubMedGoogle Scholar
• LILLO M, ORENGO S, CERNO C, HARRIS R: Pulmonary and disseminated infections due toMycobacterium kansaii: a decade of experience. Rev. Infect. Dis. (1990) 12:760–767.
   PubMedGoogle Scholar
• WITZIG R, FRANZBLAU S: Susceptibility of Mycobac- terium kansasii to ofloxacin, sparfloxacin, clarithromycin, azithromycin and fusidic acid. Antimi-crob. Agents Chenzother. (1993) 37:1997–1999.
   PubMed Web of Science ®Google Scholar
• BROWN B, WALLACE R, ONYI G: Activity of cLarithromycin against eight slowly growing species of nontuber-culosis Mycobacteria, determined by using a broth microdilution MIC system. Antimicrob. Agents Chemotber. (1992) 36:1987–1990.
   PubMed Web of Science ®Google Scholar
• YAJKO D, NASSOS P, SANDERS C, GONZALEZ P, HADLEY W: Comparison of the intracellular activities of darithromydn and erythromycin against Mycobac-terium avium complex strains in J774 cells in alveolar macrophages from human Immunodeficiency virus type 1-infected individuals. Antimicrob. Agents Chemother. (1992) 36:1163–1165.
   PubMed Web of Science ®Google Scholar
• PERRONNE C, G1KAS A, TRUFFOT-PERNOT C, GROSSET J, POCIDALO J, VILDE J: Activity of clarithromycin, sul-fisosiazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages. Antimicrob. Agents Chemother. (1990) 34:1508–1511.
   PubMed Web of Science ®Google Scholar
• COHEN Y, PERRONNE C, TRUFFOT-FERNOT C, GROSSFT J, VIDE J, POCLDALD J: Activities of WIN-57273, minocy-cline, clarithromycin, and 14-hydroxy-clarithromycin against mycobacterium avium complex in human macrophage. Antimicrob. Agents Chemother. (1992) 36:2104–2107.
   PubMed Web of Science ®Google Scholar
• MOR N, HEIFE1S L: MICs and MBCs of clarithromycin against Mycobacterium avium within human macro-phages. Antimicrob. Agents Chemother. (1993) 37:111–114.
   PubMed Web of Science ®Google Scholar
• ONYEJI C, NIGHTINGALE C, NICOLAU D, QUINTILIANI R: Efficacies of liposome-encapsulated clarithromycin and ofloxacin against Mycobacterium avium-M. in-tracellulare complex in human macrophages. Antimi-crob. Agents Chemother. (1994) 38:523–527.
   PubMed Web of Science ®Google Scholar
• ICLEMENS S, DESTEFANO M, CYNAMON M: Activity of clarithromycin againstMycobacterium avium complex infection in beige mice. Antimicrob. Agents Chemother. (1992) 36:2413–2417.
   PubMed Web of Science ®Google Scholar
• JI B, LOUNIS N, TRUFFOT-PERNOT C, GROSSET J: Selection of resistant mutant of Mycobacterium avium in beige mice by clarithromycin monotherapy. Antimi-crob. Agents Chemother. (1992) 36:2839–2840.
   PubMed Web of Science ®Google Scholar
• ARAUJO F, PROKOCIMER P, LINT, REMINGTON J: Activity of clarithromycist alone or in combination with other drugs for treatment of murine toxoplasmonsis. Antimi-crob. Agents Chemother. (1992) 36:2454–2457.
   PubMedGoogle Scholar
• ALDER J, MITTEN M, JARVIS K, GUPTA P, CLEMENT J: Efficacy of clarithromycin for treatment of experimen-tal Lyme Disease in vivo. Antimicrob. Agents Chemother. (1993) 37:1329–1333.
   PubMed Web of Science ®Google Scholar
• NOTARIO G, GUPTA S: Effect of clarithromycin on symptoms of MAC infection among HIV-positive pa-tients. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 296.
   Google Scholar
• CRAFT J, HENRY D: Safety and efficacy of clarithromycin in the treatment of disseminated Mycobacterium avium complex infection. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 295.
   Google Scholar
• CRAFT J: Survival in AIDS patients treated with clarithromycin for disseminated MAC infection. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 293.
   Google Scholar
• MERRIEN D, BILLAUD E, RELIQLTET V, MOINARD D, RSFFO F: Clarithromycin for the treatment of disseminated Mycobacterium avium infection in AlDs: Bacteriologi-cal and clinical assessment in 25 cases. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 294.
   Google Scholar
• NOTARIO G, HENRY D: Safety of clarithromycin In combination with other asaimycobacterial drugs. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 297.
   Google Scholar
• CRAFT J, NOTARIO G: Safety of clarithromycin in the treatment of disseminated nontuberculosis mycobacte-rial infection. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 216.
   Google Scholar
• DAUTZENBERG B, CHAUVIN J, PITIE SALPETRIERE GH: Treatment of non-tuberculosis mycobacteria. The French experience with clarithromycin. 2nd Interna-tional conference on the macrolides, azalides and strepto-gramins. Venice, Italy (1994), Abstract No. 300.
   Google Scholar
• COULSTON D, WOOD C: Clarithromycin for the preven-tion of Mycobacterium avium complex in patients with AIDS. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 298.
   Google Scholar
• SONNABEND J, SMITH R: Clarithromycin for Mycobacterium avium complex prophylaxis in AIDS. 2nd Inter-national conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 303.
   Google Scholar
• PAYNE D: A retospective study of clarithromycin as primary prophylaxis for MAC disease. 2nd International conference on the macrolides, azalides and streptogamins. Venice, Italy (1994), Abstract No. 302.
   Google Scholar
• SONNABEND J, COULSTON D, PAYNE D: Clarithromycin for Mycobactetlum vium complex prophylaxis in pa-tients with AIDS. 34th Interscience Conf on Antimicrob. Agents Chemother. Orlando, US (1994), Abstract No. 1189.
   Google Scholar
• GROSSMAN H, GREIGER-ZANLUNGO P, SONNABEND J, SENIOR S: Calrithromycin 500 mg BID as primary pro-phylaxis for diVIAC disease. 34th Interscience Conf on Antimic rob. Agents Chemother. Orlando, US (1994), Abstract No. 1191.
   Google Scholar
• BAKER R, NORRIS S: Clarithromycin prophylaxis against MAC in AIDS. 34th Interscience Conf on Antimicrob. Agents Chemother. Orlando, US (1994), Abstract No. 1193.
   Google Scholar
• KEITH P, SCHILLER T: Clarithromycin as primary pro-phylaxis in patients with AIDS. 34th Interscience Conf on Antimicrob. Agents Chemother. Orlando, US (1994), Abstract No. 1195.
   Google Scholar
• RANA K, DARNOWSKI J, COPELAND D, STRAYER A, PI-VARNIK P, DUDLEY M: Clarkhromycin (CLR) does not affect intrcellular concentrations of phosphorylated metabolites of zidovudine ( ZDV). 34th Interscience Conf on Antimicrob. Agents Chemother. Orlando, US (1994), Ab-stract No. 1197.
   Google Scholar
• RAFFI F, STRUILLOU L, NININ E, RELIQUET V, BILLALTD E, M1LPIED B: Breakthrough cerebral toxoplasmosis in AIDS patients treated with cLirithromycin. 2nd Interna-tional conference on the macrolides, azalides and strepto-gramins. Venice, Italy (1994), Abstract No. 305.
   Google Scholar
• FERNANDEZ-MARTIN J, LEPORT C, MORLAT P, MEYOHAS M, CHAUVIN J, VILDE J: Pyrimethamine-clarithromycin combination for therapy of acute Toxoplasma en-cephalitis in patients with AIDS. Antimicrob, Agents Chemother. (1991) 35:2049–2052.
   PubMed Web of Science ®Google Scholar
• AYNILIAN G, CRAFT J: Clarithromycin susceptibility and Helicobacter pylori infection. 2nd International confer-ence on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 316.
   Google Scholar
• LOGAN R, SCHAUFELBERGER H, GUMMETT P, BARTON J, MISLEWICZ J: Eradication of Helicobacter pylori with dual therapy. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 317.
   Google Scholar
• LOGAN R, GUMMETT P, WALKER M, KARIM Q, BARTON J, MISIEWICZ J: Treatment of Helicobacter pylori gastritis and duodenal ulcer disease. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 318.
   Google Scholar
• KIRST H, LEEDS J, PASCHAL J, MARTYNOW J: Stereospecific modification of erythromycin derivatives. In: Re-cent Advances in the Chemistry of Anti-infective Agents. Bentley PH, Ponsford R (Eds.), The Royal Society of Chem-istry, Cambridge, UK (1993):67–78.
   Google Scholar
• SLAWINSKI W,BOJARSKA-DAHLIG H, GLABSKI T, DZIEGIELEWSICA I, BIEDRZYCKI M, NAPERTY S: The struc-ture of erythromycin A cyclic carbonate. Reel Tray. Cbim Pays-Bas. (1975) 94:236–238.
   Google Scholar
• KOLWAS J: Erythromycin A carbonate. Drugs Today. (1981) 17:26–27.
   Google Scholar
• MANNISTO P, VILUKESELA M: Hepatotoxicity of macrolides. J. Antimicrob. Chemother. (1990) 25:476–477.
   Web of Science ®Google Scholar
• BOJARSKA-DAHLIG H: Hepatotoxicity of macrolide anti-biotics. J. Antimicrob. Chemother. (1990) 25:475–476.
   PubMed Web of Science ®Google Scholar
• EDWARDS C, LARTEY P, PAGANO T: Novel 3'-fluoro-erythromycin derivatives. 206th National meeting of the American Chemical Society, Chicago, USA (1993), Abstract MEDI–164.
   Google Scholar
• BRAIN E, FORREST A, HUNT E, SHILLINGFORD C, WILSON J: Erythromycin A-oxime 11,12- carbonate and its OXIMC ethers. J. Antibiotics (1989) 42:1817–1822.
   PubMed Web of Science ®Google Scholar
• BAKER W, CLARK J, STEPHENS R, KIM K: Modification of macrolide antibiotics. Synthesis of 11-cleoxy-11(car-boxyamino)-6-0-methylerythromycin A 11,12-(cyr_lic esters) via an intramolecular Michael reaction of O-car-bamates with an a,I3-unsaturated ketone. J. Org. Chem. (1988) 53:2340–2345.
   Google Scholar
• HUNT E, ICNOWLES D, SHILLINGFORD C, ZOMZYA I: Erythromycin A 11,12-methylene acetaL J. Antibiotics(1989) 41: 1644-1648.
   Google Scholar
• HAUSKE J, GUADINLIANA M, KOSTEK G: Aglycon modi-fications of erythromycin A: Regionspecific and stereospecific elaboration of the C-12 position.1 Org. Chem. (1987) 52:4622–4625.
   Google Scholar
• WILSON J, DURODIE J, FOULSTONE: Hydrolysis of semi-synthetic macrolides by erythromycin esterase from Escbericbia coll. j Antimicrob. Chemother. (1988) 22:84–86.
   PubMed Web of Science ®Google Scholar
• FERNANDES P, BAKER W, FREIBERG L, HARDY D, MCDON- ALT) E: New macrolides active against Streptococcus pyogenes with inducible or constitutive type of macrolide-lincosamicle-streptogramin B resistance. An-timicrob. Agents Chemother. (1989) 33:78–81.
   PubMed Web of Science ®Google Scholar
• AGOURIDAS C, BENEDETTI Y, DENTS A, FROMENTIN C, GOUIN S, MARTRET D, CHANTOT J: Ketolides, a new distinct semi-synthetic class of macrolkles. 34th Inter-science Conf on Antimicrob. Agents Chemother. Orlando, US (1994), Abstract No. F164.
   Google Scholar
• AGOURIDAS C, COLLE1TE P, MAUVAIS P, CHANTOT J: Ketolides, a new distinct semi-synthetic class of macrolides: Studies on the mechnnism of action. 34th Interscience Conf on Antimicrob. Agents Chemother. Or-lando, US (1994), Abstract No. F166.
   Google Scholar
• AGOURIDAS C, BONNEFOY A, CHANTOT J: Ketolides, a new distinct semi-synthetic class of macrolides: In vitro and in-vivo antibacterial activies. 34th Interscience Conf on Antimicrob. Agents Chemother. Orlando, US (1994), Ab-stract No. F168.
   Google Scholar
• DJOKIC S, KOBREHEL G, LAZAREVSKI G: Erythromycin series. XII. Antibacterial in vitro evaluation of 10-dilly-dro-10-deoxo-11-azaerythromycin A: synthesis and structure-activity relationship of its acyl derivatives. J. Antibiotics (1987) 40:1006–1015.
   Google Scholar
• BRIGHT G, NAGEL A, BORDNER J, DESAI K, DIBRINO J, NOWAKOWSKA J, VINCENT L, WATROUS R, SCIAVOLINO F, ENGLISH A, RETSEMA J, ANDERSON M, BRENNAN L, BOROVOY R, CIMOCHOWSKI C, FAIELLA J, GIRARD A, GIRARD D, HERBERT C, MANOUSOS M, MASON R: Synthe-sis in vitro and in vivo activity of novel 9-deoxo-9a-aza-9a-homoerythromycin A derivatives; a new class of macrolide antibiotics, the azalides. J. Antibiotics (1988) 41:1029–1047.
   PubMed Web of Science ®Google Scholar
• DUNKIN K, JONES S, HOWARD A: The in-vitro activity of CP-62,993 against Haemopbilus influenzae, Bran-bamella catarrbalis, staphylococci and streptococcL J. Antimicrob. Chemother. (1988) 21:405–411.
   Google Scholar
• RETSEMA J, GIRARD A, SCHELKLY W, MANOUSOS M, ANDERSON M, BRIGHT G, BOROVOY R, BRENNAN L, MASON R: Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered ring macrolide with Improved potency against gram-negative organisms. Antimicrob. Agents Chemother. (1987) 31:1939–1947.
   PubMed Web of Science ®Google Scholar
• TAYOR D, NICHOLAS C: In vitro susceptibilities of Cam- pylobactericluni and Campylobacter colt to azithromy-an and erythromycin. Antimicrob. Agents Chemother. (1991) 35:1917–1918.
   PubMed Web of Science ®Google Scholar
• CAPOBIANCO J, GOLDMAN R: Erythromycin and az- ithromycin transport into Haemopbilus influensae ATCC 19418 under condition of depressed proton mo-tive force. Antimicrob. Agents Chemother. (1990) 34:1787–1791.
   PubMedGoogle Scholar
• EDELSTEIN P, EDELSTEIN M: In vitro activity of azithromycin against clinical isolates of Legionella spe-des. Antimicrob. Agents Chemother. (1991) 35:180–181.
   PubMed Web of Science ®Google Scholar
• RYLANDER M, HALLANDER H: In vitro comparison of the activity of doxycydine, tetracycline, erythromycin and anew macrolide, CP-62993, against Mycoplasma pneu-moniae, Mycoplasnta bonsinis and Ureaplasma urea-brticum. Scand. J. Infect. Dis. (1988) 53(Suppl.):12–17.
   Google Scholar
• WALSH M, KAPPUS E, QUINN T: In vitro evaluation of CP-62993, erythromycin, clindamycin, and tetracycline against Cbamydia tracbotnatis. Antimicrob. Agents Chemother. (1987) 31:811–812.
   PubMed Web of Science ®Google Scholar
• WELSH L, GAYDOS C, QUINN T: In vitro evaluation of activities of azithromycin, erythromycin, and tetracy-dine against Cblamydia tracbomatis and Cblamydia pneumoniae. Antimicrob. Agents Chemother. (1992) 36:291–294.
   PubMed Web of Science ®Google Scholar
• AGACFIDAN A, MONCADA J, SCHACHTER J: In vitro activity of azithromycin (CP-62,993) against Cbamydia tracbomatis and Cbamydia pneumoniae. Antimicrob. Agents Chemother. (1993) 37:1746–1748.
   PubMed Web of Science ®Google Scholar
• HAMMERSCHLAG M, QUMEI K, ROBLIN P: In vitro activi-ties of ailthromycin, cLirithromycin, L-ofioxacin, and other antibiotic against Cbamydia pneumoniae. Antimi-crob. Agents Chemother. (1993) 36:1573–1574.
   Google Scholar
• BERMUDEZ L, YOUNG L: Activities of amikacin, roxithromycin, and azithromydn alone or in combina-tion with tumor nercosis factor against Mycobacterium avium complex. Antimicrob. Agents Chemother. (1988) 32:1149–1153.
   PubMed Web of Science ®Google Scholar
• CHAMBERLAND S, KIRST H, CURRENT W: Comparative activity of macrolides against Toxoplasma gondii dem-onstrating utility of an in vitro microassay. Antimicrob. Agents Chemother. (1991) 35:903–909.
   PubMed Web of Science ®Google Scholar
• CHANG H, PECHERE J: In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) on Toxoplasma gondiL Antimicrob. Agents Chemother. (1988) 32:524–529.
   PubMed Web of Science ®Google Scholar
• CANT1N L, CHAMBERLAND S: /n vitro evaluation of the activities of azithromycin alone and combined with pyrimethamine againstToxoplasmagotulii. Antimicrob. Agents Chemother. (1993) 37:1993–1996.
   PubMed Web of Science ®Google Scholar
• PFEFFERKORN E, BOROTZ A: Comparison of mutants of Toxoplasma gondii selected for resistance to az-ithromydn, spiramycin, or clindamycin. Antimicrob. Agents Chemother. (1994) 38:31–37.
   PubMed Web of Science ®Google Scholar
• JOHNSON R, KODNER C, JURKOVICH P, COLLINS J: Com-parative in vitro and in vivo susceptibilities of the Lyme disease spirochete Borrelia butgdotferi to cef-uroxime and other antimicrobials. Antimicrob. Agents Chemother. (1990) 34:2133–2136.
   PubMed Web of Science ®Google Scholar
• PAJUKANTA R, ASIKAINEN S, SAARELA M, ALALUUSULA A, JOUSIMLES-SOMER H: /n vitro activity of azithromycin compared with that of erythromycin againstA ctinobac-illus actinomycetemcomitans. Antimicrob. Agents Chemother. (1992) 36:1241–1243.
   PubMed Web of Science ®Google Scholar
• MIZUKANE R, HIRAKATA Y, KAKU M, ISHII Y, FURUYA N, ISHIDA K, KOGA H, KOHNO S, YAMAGUCHI K: Compara-tive in vitro exoenzyrne-suppressing activities of az-ithromycin and other macrolide antibiotics against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. (1994) 38:528–533.
   PubMed Web of Science ®Google Scholar
• MIZUKANE R, KAKU M, ISHIDA K, TAKEMURA H, TANAKA H, YOSHIDA R, TOMONO K, KOGA H, KOHNO S, USUI T, HARA K: Comparative in vitro exoenzyme-suppressing activities of azithromycin and other macrolide antibi-otics against Pseudomonas aeruginosa. 34th Inter-science Conf on Antimicrob. Agents Chemother. Orlando, US (1994), Abstract No. B42.
   Google Scholar
• GORBY G, MCGEE Z: Antimicrobial interference with bacterial mechanisms of pathogenicity: Effect of sub-MIC azithromycin on Gonococcal piliation and attach-ment to human epithelian cells. Antimicrob. Agents Chemother. (1990) 34:2445–2448.
   PubMed Web of Science ®Google Scholar
• BONNET M, VAN DER AUWERA P: In vitro and in vivo intraleukocytic accumulation of azithromydn (CP-62,993) and its influence on ex vivo leukocyte chemilu-minescence. Antimicrob. Agents Chemotber. (1992) 36:1302–1309.
   PubMed Web of Science ®Google Scholar
• BERMUDEZ L, INDERLIED C, YOUNG L: Stimulation with cytokines enhances penetration of azithromycin into human macrophages. Antimicrob. Agents Chemother. (1991) 35:2625–2629.
   PubMed Web of Science ®Google Scholar
• GERBAUX C, PLRET J, MONTENEZ J, 'TUL10ENS P: Az-ithromycin (Az) increases the activities of several lysosomal enzymes when measured in Lysates of rat embryo fibroblasts incubated with this antibiotic. 34th Interscience conj. on Antimicrob. Agents Chemother. Or-lando, US (1994), Abstract No. A108.
   Google Scholar
• GIRARD A, GIRARD D, ENGLISH A, GOOTZ T, CIMOCHOWSKI C, FAIELLA J, HASKELL S, RETSEMA J: Pharma-cokinetic and in vivo studies with azithromycin (CP-62,993), anew macrolide with an extended half-life and excellent tissue distribution. Antimicrob. Agents Chemother. (1987) 31:1948–1954.
   PubMed Web of Science ®Google Scholar
• STAMLER D, EDELSTEIN M, REN J, CHEN Z, LIU M, EDEL-STEIN P: Azithromycin pharmacokinetics in L pneuo-pbila-infected guinea pigs and alveolar macrophages. 33rd Interscience Conf on Antimicrob. Agents Chemother. New Orleans, US (1993), Abstract No. 955.
   Google Scholar
• STAMLER D, EDELSTEIN M, EDELSTEIN P: Azithromycin pharrnacokinetics and intracellular concentrations in Legionella pneumopbila-infected and uninfected guinea pigs and their alveolar macrophages. Antimicrob. Agents Chemotber. (1994) 38:217–222.
   PubMed Web of Science ®Google Scholar
• ARAUJO F, SHEPARD R, REMINGTON J: In vivo activity of the antibiotics macrolides azithromydn, roxithromy-cin and spiramycln against Toxoplasma gondii. Eur. J. Clin. Micro biol. Infect. Dis. (1991) 10:519–524.
   PubMed Web of Science ®Google Scholar
• ARAUJO F, REMINGTON J: Synergistic activity of az ithromycin and gamma interferon in murine toxoplas-mosis. Antimicrob. Agents Chemother. (1991) 35:1672–1673.
   PubMed Web of Science ®Google Scholar
• BROWN S, EDWARDS F, BERNARD E, TONG W, ARM- STRONG D: Azithromycin, rifabutin, and rffapentine for treatment and prophylaxis of Mycobacterium avium complex in rats treated with cyclosporin. Antimicrob. Agents Cbernother. (1993) 37:398–402.
   PubMed Web of Science ®Google Scholar
• VALLEE E, AZOULAY-DUPUIS, POCIDALO J, BERGOGNE- BEREZIN E: Activity and local delivery of azithromydn In a mouse model of Haemopbilus influenzae lung Infection. Antimicrob. Agents Chemother. (1992) 36:1412–1417.
   PubMed Web of Science ®Google Scholar
• AMACHER D, SCHOMAKER S, RETSEMA J: Comparison of the effects of the new azalide antibiotic, azithromydn, and erythromycin estolate on rat liver cytochrome P-450. Antimicrob. Agents Chemother. (1991) 35:1186–1190.
   PubMed Web of Science ®Google Scholar
• AMSDEN G: Review of drug interaction profile of az-ithromycin. 2nd International conference on the macrolides, azalides and stitptogramins. Venice, Italy (1994), Abstract No. 218.
   Google Scholar
• FOULDS G, SHEPARD R, JOHNSON R: The pharmacoki- netics of azithromycin in human serum and tissues. J. Antimicrob. Chemother. (1990)25(Suppl. A2):73–82.
   Google Scholar
• RETSEMA J, GIRARD A, GIRARD D, MILISEN B: Relation-ship of high tissue concentrations of azithromycin in human serum and tissues. J. Antimicrob. Chemother. (1990)25(Suppl. A2):83–89.
   Google Scholar
• '3VILDFEUER A, LAUREN H, LEITOLD M, ZIMMERMANN T: Comparison of the pharmacokinetics of three-day and five-day regimens of azithromycin in plasma and urine. J. Antimicrob. Chemother. (1993) 31(Suppl. E):51–56.
   Google Scholar
• CHAVE J, MUNAFO A, CHATTON J, DAYER P, GLAUSER M, BIOLLAZ J: Once-a-week azithromycin in AIDS patients: Tolerability, kinetics, and effects on zidovudine dispo-sition. Antimicrob. Agents Chemotber. (1992) 36:1013–1018.
   PubMed Web of Science ®Google Scholar
• DUNNE M, WILLIAMS D: Absorption of azithromycin in patients with AIDS. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 205.
   Google Scholar
• SHIBA K, SHINDO N, SAKAI D: Pharmacokinetics of azithromycin in patients with renal failure. 2nd Inter-national conference on the macrolides, azalides and strepto-gramins. Venice, Italy (1994), Abstract No. 188.
   Google Scholar
• PUKANDER J: Penetration of azithromycin into middle ear effusions in acute and secretory otitis media in children. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 199.
   Google Scholar
• FOULDS G, FERRAINA R, FOUDA H, JOHNSON R, KAMEL A, SHEPARD R, FALONE R, HANNA C: Azithromycin concentrations in gallbladder, hepatic tissue, and bile following a five day regimen in man. 33rd Interscience Conf on Antimicrob. Agents Chemother. New Orleans, US (1993), Abstract No. 738.
   Google Scholar
• MULLER O: A multicentre trial comparing azithromycin and roxithromycin in the treatment of adults with acute upper respiratory tract infections. 2nd International conference on the macrolides, azalides and sueptogramins. Venice, Italy (1994), Abstract No. 230.
   Google Scholar
• MULLER O: Comparison of azithromycin versus clarithromycin in the treatment of patients with upper respiratory tract infections. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 228.
   Google Scholar
• KHURANA C, MCLINN S, SCOTTS-DALE A, BLOCKS, BARD-STOWN K, PICHICHERO M: Trial of azithromycin (AZ) vs augmentin (AUG) for the treatment of acute otitis media (AOM). 34th Interscience Conf on Antimicrob. Agents Chemotber. Orlando, US (1994), Abstract No. M59.
   Google Scholar
• STILL J: Treatment of Streptococci pharyngitis in chil-dren with five days of azithromycin suspension. 34th Interscience Conf on Antimicrob. Agents Cbemother. Or-lando, US (1994), Abstract No. M67.
   Google Scholar
• LAURENT K: Efficacy, safety and toleration of azithromy-cin versus roxithromycin in the treatment of acute lower respiratory tract infections. 2nd International con-ference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 264.
   Google Scholar
• ZACHARIAH J: A randomized comparative study of a short course of azithromycin versus a 10-day course of anioxyrillin/davulanic acid in the treatment of patients with lower respiratory tract infections. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 259.
   Google Scholar
• HAMMERSCHLAG M, ROBLIN P, CASSELL G: Microbiologic efficacy of azithromycin for the treatment of commu-nity-acquired lower respiratory tract infection due to Chlamydia pneumoniae. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 283.
   Google Scholar
• AMLAND P, ANDENAES K, SAMDAL F,LINGAAS E, SANDSMARK M, ABYHOLM F, GIERCKSKY K: A prospec-tive, double blind placebo controlled a7lahromydn in posoperative would infections in plastic surgery. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 309.
   Google Scholar
• WEBER K, WILSKE B, PREAC-MURSIC V, THURMAYR R: Azithromydn versus penicillin V for the treatment of early Lyme borreliosis. Infections (1993) 21:367–372.
   PubMed Web of Science ®Google Scholar
• SCHONWALD S, BARSIC B, FRANCE'TIC I, KILNAR I: Clini-cal study of intravenous azithromycin. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 288.
   Google Scholar
• HOPKINS S, WILLIAMS D, BURNSIDE R: Azithromycin safety in children: US clinical trials experience. 2nd International conference on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 211.
   Google Scholar
• TREADWAY G, PONTANI D: Worldwide pediatric safety • experience of azithromycin. 2nd International confer-ence on the macrolides, azalides and streptogramins. Venice, Italy (1994), Abstract No. 211.
   Google Scholar
• FINCH R, RIDGWAY G, TOWER K (Eds.): Azithromycin: clinical experience. J. Antimicrob. Chemotber. (1993) 31(Suppl. E).
   Google Scholar
• WILKENING R, RATCLIFFE R, SZYMONIFKA M, SHANKARAN K, MAY A, BLIZZARD T, HECK J, HERBERT C, GRAHAM A, BART1ZAL K: Synthesis and in vitro activities of 9-deoxo-8a-aza-8a-homoerythromycin derivatives, a new series of azalicle antibiotics. 33rd Interscience Conf. on Antimicrob. Agents Cbemother. New Orleans, US (1993), Abstract No. 426.
   Google Scholar
• GILL C, ABRUZZO G, FLATTERY A, SMITH J, KROPP H, BART1ZAL K: In vivo evaluation of three acid-stable 07nlide compounds, L-701,667, L-708,299 and L-708,365 compared to erythromycin, azithromycin and clarithromycin. 33rd Interscience Conf. on Antimicrob. Agents Chemother. New Orleans, US (1993), Abstract No. 427.
   Google Scholar
• PELAK B, GERCICENS L, ICROPP H: Tissue distribution and pharmacokinetics of novel a7211de 8a-aza-8a-homo-erythromycin derivatives. 33rd Interscience Conf. on An-timicrob. Agents Chemother. New Orleans, US (1993), Abstract No. 428.
   Google Scholar
• EADY E, ROSS J, COVE J, HOLLAND K, CUNLIFFE W: Macrolide-lincosamide-streptogramin B (MIS) resis-tance in cutaneous propionibacteria: definition of pheno-types.f Antimicrob. Chemother. (1989) 23:493–502.
   PubMed Web of Science ®Google Scholar
• LECLERCQ R, COURVALIN P: Bacterial resistance to macrolide, lincosamkle, and streptogramin antibiotics by target modification. Antimicrob. Agents Chemotber. (1991) 35:1267–1272.
   PubMed Web of Science ®Google Scholar
• LECLERCQ R, COURVALIN P: Intrinsic and unusual resis-tance to macrolicle, lincosamide and streptogramin antibiotics in bacteria. Antimicrob. Agents Chemother. (1991) 35:1273–1276.
   PubMed Web of Science ®Google Scholar
• DUBNAU D: Translational attenuation: the regulation of bacterial resistance to the macrolide-lincosamide-streptogramin B antibiotics. Crit. Rev. Biocbem. (1986) 16:103–131.
   Google Scholar
• WEISBLUM B: Inducible erythromycin resistance in bac-teria. Br. Med. Bull. (1984) 40:47–53.
   PubMed Web of Science ®Google Scholar
• FERNANDES P, BAKER W, FREIBERG L, HARDY D, MCDON- ALD E: New macrolides active against Streptococcuspyogenes with inducible or constitutive type of macrolide-lincosamide-streptogramin B resistance. An-timicrob. Agents Chemother. (1989) 33:78–81.
   PubMed Web of Science ®Google Scholar
• REIG M, MORENO A, BAQUERO F: Resistance of Pep- stostreptococcus spp. to macrolides and linosamides:inducible and constitutive phenotypes. Antimicrob. Agents Chemotber. (1992) 36:662–664.
   PubMedGoogle Scholar
• GARDEE Y, KIRBY R: The incidence of inducible macrolide-lincosamide-streptogramin B resistance in methicillin-resistant staphylococci in clinical isolates from the Eastern Cape area of South Africa. Lett. Appl. Micro bio. (1993) 17:264–268.
   PubMed Web of Science ®Google Scholar
• VANUFFEL P, DIDIAMBATT1STA M, MORGAN E, COCITO C: Identification of a single base change in ribosomal RNA leading to erythromycin resistance. J. Biol. Chem. (1992) 267:8377–8382.
   PubMed Web of Science ®Google Scholar
• YAN W, TAYLOR D: Characterization of erythromycin resistance in Campylobacterfefuni and Campylobacter coll. Antimicrob. Agents Chemother. (1991) 35:1989–1996.
   PubMed Web of Science ®Google Scholar
• GOIDMAN R, CAPOBIANCO J: Role of an energy depend-ent efflux pump in plasmid pNE24-mediated resistance to 14-,15-membered macrolides in Staphylococcus epidermidis. Antimicrob. Agents Chemother. (1990) 34:1973–1980.
   PubMed Web of Science ®Google Scholar
• ROSS J, EADY E, COVE J, CUNLIFFE W, BAUMBERG S, WOOTON J: Inducible erythromycin resistance in staphylococci is encoded by a member of the ATP-bind-ing transport super-gene family. Mol. Microbiol. (1990) 4:1207–1214.
   PubMed Web of Science ®Google Scholar
• NASH K, INDERLIED C: Genetic basis of resistance to clarithromycin (CLMO) in Mycobacterium avium (MAC). 34th Interscience Conf. on Antimicrob. Agents Chemother. Orlando, US (1994), Abstract No. C2.
   Google Scholar
• ANDREMONT A, GERBAUD G, COURVALIN P: Plasmid-mediated high level resistance to erythromydn in Es-chericbia coiL Antitnicrob. Agents Chemother. (1986) 29:515–518.
   PubMed Web of Science ®Google Scholar
• ARTHUR M, ANDREMONT A, COURVAL1N P: Distribution of erythromycin esterases and rRNA methylation genes In members of family enterobacteriaceae highly resis-tant to erythromycin. Antimicrob. Agents Chemother. (1987) 31:404–409.
   PubMed Web of Science ®Google Scholar
• O'HARA K, KANDA T,OHMIYA K, EBISU T, KONO M: Purification and characterization of macron& 2'-phos-photransferase from a strain of Escbericbia coil that is highly resistant to erythromycin. Antimicrob. Agents Chemother. (1989) 33:1354–1357.
   PubMed Web of Science ®Google Scholar
• CUNDIFFE E: Glycosylation of maroclide antibiotics in extracts of streptontyces lividans. Antimicrob. Agents Chemothet: (1992) 36: 348–352.
   PubMedGoogle Scholar
• WONDRACK L, MASSA M, YANG B, SUTCLIFFE J: A clinical strain of Staphylococcus aureus produces a macrolide-specific esterase. 1st Intern. Conf. Antibiotic Res: Impact on Discovery. Englewood, CO, USA (1994), Abstract No. P7.
   Google Scholar
• ZARA G, THOMPSON H, PILOT M, RITCHIE H: Effects of erythromycin on gastrointestinal tract motility. J. An-timicrob. Chemother. (1985) 16:175–179.
   PubMed Web of Science ®Google Scholar
• BROWN J: Presence of a gastric motor-stimulating prop-erty in duodenal extracts. Gastroenterology (1967) 52:225–229.
   PubMed Web of Science ®Google Scholar
• PEETERS T, MAITHUS G, DEPOORTERE I, CACHET T, HOOGMARTENS J, VANTRAPPEN G: Erythromycht is a motilin receptor agoinst. Am.J. Physiol. (1989) 257:G469–G474.
   Google Scholar
• ANNESE V, JANSSENS J,VANTRAPPEN G, TACK J, PEETERS T, WILLEMSE P, VAN CUTSEM E: Erythromycin acceler-ates gastric emptying by inducing contractions and Improved gastroduodenal coordination. Gastroenterol-ogy (1992) 102:823–828.
   PubMed Web of Science ®Google Scholar
• ITOH Z, OMURA S: Motilide, a new family of macrolide compounds mimicking motilin. Dis. Dis. Sci. (1987) 32:915 (Abstract).
   Google Scholar
• DEPOORTERE 1, PEETERS T, MAITHUS G, CACHET T, HOOGMARTENS J, VANTRAPPEN G: Structure-activity re-lationship of erythromycin related macrolides in in-dudng contractions and in displacing bound motilin in rabbit duodenum. J. Gastrointest. Motil. (1989) 1:150–159.
   Google Scholar
• DEPOORTERE I, PEETERS T, VANTRAPPEN G: The eryth- romycin derivative EM-523 is a potent motilin agoinst In man and in rabbit. Peptides (1990) 11:515–519.
   PubMedGoogle Scholar
• TSUZUKI K, SUNAZUKA T, MARUI S, TOYODA H, OMURA S: Motilides, macrolides with gastrointesstinal motor stimulating activity. LO-Substituted and tertiary N-sub-stituted derivatives of 8,9-anhydroerythromycin A 6,9-hemiacetaL Chem. Pharm. Bull. (1989) 37(10):2687–2700.
   Google Scholar
• TSUZUKI K, SUNAZUKA T, MARUI S, TOYODA H, OMURA S: Motilides, macrolkles with gastrointesstinal motor stimulating activity. IL Quaternary N-substituted deriva-tives of 8,9-anhydroerrythromycin a 6,9-hemiacetal and 9,9-dihydroerythromycin a 6,9-epoxide. Chem. Pharm. Bull. (1989) 37(10):2701–2709.
   Google Scholar
• KOGA H, SATO T, TSUZUKI K, TAKANASHI H: Macrolide type motilin receptor agonists: Assessment of the bio-logical value of the 2'- and 4'-hydroxyl groups of acid-stable 8,9-atthydroerythromycin A 6,9-hemiacetals. Bioorganic & Med. Chem. Lett. (1994) 4(13):1649–1654.
   Web of Science ®Google Scholar
• FAGHIH R, LARTEY P, FREIBERG L, KLEIN L, NELLANS H, PETERSEN A: 9-Deoxo-4"-deoxy-6,9-epoxyerythromy-cins: potent prokinetic agents. 206th ACS national meet. Chicago, US (1993), Abstract No. MEDI 239.
   Google Scholar
• ABBOTT LAB. US5075289.
   Google Scholar
• ABBOTT LAB. US5217960–A
   Google Scholar
• ABBOTT LAB. US5288709–A
   Google Scholar
• MERCK & CO. US5215980–A
   Google Scholar
• PIERREL SPA JP93066396–B
   Google Scholar
• TOYO JOZO KK JP93070636–B
   Google Scholar
• TAISHO PHARM CO LTD. W09321199–A1
   Google Scholar
• ROUSSEL-UCLAF FR2697524–A1
   Google Scholar
• ROUSSEL-UCLAF EP596802–A1
   Google Scholar
• TAISHO PHARM CO. LTD. W09321200
   Google Scholar
• TAISHO PHARM CO. LTD. W09313115–A1
   Google Scholar
• TAISHO PHARM CO. LTD W09313116–A1
   Google Scholar
• ROUSSEL-UCLAF FR26914644-Al
   Google Scholar
• YAMANOUCHI PHARM CO LTD. EP596112-Al
   Google Scholar
• MERCK & CO. EP54’9340-Al
   Google Scholar
• ABBOTT LAB. EP579770–A1
   Google Scholar
• CHUGAI SEIYAKU ICK W09324509–A1
   Google Scholar
• KlTASATO KENKYUSHO EP215355–B1
   Google Scholar
• KALICHEMIE PHAW GMBH EP550895-Al
   Google Scholar
• ABBOTT LAB.WO9313780-Al
   Google Scholar